Dec 12, 2020
NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)
UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...
415
Dec 12, 2020
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma NCT04405167: Phase 1: Tasquinimod for the Treatment...
24
Dec 12, 2020
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM Multiple Myeloma
NCT04309981: Phase 1/2: Humanized CART Directed Against BCMA (ARI0002h) in RRMM to Proteasome Inhibitors, Immunomodulators and Anti-CD38...
219
Dec 12, 2020
NCT04512235: Phase 3: To Evaluate Effectiveness & Safety of CAEL-101 in Stage IIIa AL Amyloidosis
CAEL-101 Amy NCT04512235: Phase 3: A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL...
354
Dec 12, 2020
Myeloma Canada: Patient Handbook - Myeloma Bone Disease
Myeloma Canada: Patient Handbook - Myeloma Bone Disease Click here to read more: https://myeloma.ca/pixms/uploads/serve/ckeditor/210804_w...
55
Dec 12, 2020
NCT04566328: Phase 3 - Testing the Use of Combination Therapy in NDMM, the EQUATE Trial - EAA181
EQUATE TRIAL EAA181 / EQUATE Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE...
553
Dec 11, 2020
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)
NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma...
133
Dec 11, 2020
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of RRMM Myeloma
NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma...
55
Dec 11, 2020
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
NCT04244656: Phase 1 -A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma This is a...
171
Dec 11, 2020
NCT04398680: Phase 1: Belantamab Mafodotin With Normal & Impaired Hepatic Function (DREAMM 13) RRMM
NCT04398680: Phase 1: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM...
61
Dec 10, 2020
IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing - COVID-19 antibodies test
IMPACT STUDY The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study The Immune Profiling with Antibody-based COVID-19...
132
Dec 10, 2020
NCT04268199: Phase 2: Exploring Self-Administration of Chemo in the Home Environment (EASE)
NCT04268199: Phase 2: A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (EASE)...
24
Dec 10, 2020
NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)
NCT04246047: Phase 3: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab,...
85
Dec 10, 2020
MGUS (Monoclonal gammopathy of undetermined significance) - > Smoldering Myeloma -> Multiple Myeloma
MGUS (Monoclonal gammopathy of undetermined significance) - > Smoldering Myeloma -> Multiple Myeloma MGUS Diagnosis: Monoclonal...
164
Dec 10, 2020
The clonoSEQ® Watch Registry
The clonoSEQ® Watch Registry Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The...
253
Dec 10, 2020
CRI - Cancer Research Institute - Cancer Immunotherapy 101 with Dr. E. John Wherry
Cancer Immunotherapy 101 with Dr. E. John Wherry Cancer Immunotherapy 101 with Dr. E. John Wherry Cancer Research Institute The basics of...
36
Dec 10, 2020
American Cancer Society: What is meant by Phase 1, Phase 2, Phase 3 Clinical Trials?
American Cancer Society: What is meant by Phase 1, Phase 2, Phase 3 Clinical Trials? What are different phases of clinical trial? Basic...
302
Dec 10, 2020
NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03
IsKPd - IFM2018-03 NCT04287855: Phase 2: Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in...
190
Dec 10, 2020
NCT04504825: Phase 3: Efficacy & Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis
NCT04504825: Phase 3: A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis...
202